乳腺癌新辅助治疗后基于乳腺MRI的疗效评估的预后价值:一项回顾性队列研究
该单中心回顾性队列研究纳入317例接受新辅助化疗及术前乳腺MRI的乳腺癌患者,比较MRI完全缓解(rCR)与病理完全缓解(pCR)对无病生存期(DFS)的影响。
要点
- rCR定义为肿瘤部位无异常强化,pCR定义为乳腺及腋窝浸润性癌消失。
- rCR与pCR一致率为79.5%(252/317),联合评估可更好分层预后。
核心结论
- 新辅助化疗后MRI与病理疗效联合评估可能更好分层乳腺癌复发风险及预后。
研究设计与样本
- 单中心回顾性队列研究,纳入317例连续接受新辅助化疗及术前乳腺MRI的乳腺癌患者,以病理为参考标准定义pCR,MRI定义rCR。
关键影像表现/征象
- rCR定义为肿瘤部位无异常强化,pCR定义为乳腺及腋窝浸润性癌消失。
- rCR 126例(39.7%),pCR 119例(37.5%),两者一致252例(79.5%)。
诊断标准与关键数值
- rCR:MRI示肿瘤部位无异常强化;pCR:病理示乳腺及腋窝浸润性癌消失。
- rCR且pCR者DFS曲线优于非rCR且非pCR者,仅rCR或仅pCR者呈中间曲线(Log-rank p=0.003)。
临床应用与阅片要点
- 阅片时按肿瘤部位无异常强化判读rCR,并与病理pCR结果对照。
- 报告中可同时注明MRI与病理缓解状态,辅助预后分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the impact of response evaluation after neoadjuvant chemotherapy (NAC) in breast cancer patients, assessed by both magnetic resonance imaging (MRI) and pathology, on disease-free survival (DFS).
METHODS: This single-center, retrospective cohort study included consecutive breast cancer patients who underwent NAC and preoperative breast MRI. Resolution of invasive carcinoma in the breast and axilla was defined as complete pathological response (pCR). Radiological complete response (rCR) was defined as the absence of abnormal enhancement in the tumor site. Kaplan-Meier estimator was used to estimate the disease-free survival on 60 months. Cox regression analysis was used to estimate hazard ratio (HR) values.
RESULTS: In total, 317 patients were included with a mean age of 47.3 years and a mean tumor size of 39.8 mm. The most common immunophenotype was luminal (44.9%), followed by triple-negative (26.8%). Overall, 126 patients (39.7%) had an rCR, while 119 (37.5%) had pCR; the radiological and pathological responses agreed in 252 cases (79.5%). During follow-up, patients who had rCR and pCR had a better DFS curve compared to patients with non-rCR and non-pCR, while those who had rCR or pCR presented an intermediate curve (Log-rank p = 0.003). Multivariate analysis showed a higher risk of recurrence in patients with non-rCR and non-pCR (HR: 5,626; p = 0.020) and those who had a complete response on MRI or pathology only (HR: 4,369; p = 0.067), when compared to patients with rCR and pCR.
CONCLUSIONS: The association of MRI and pathological responses after NAC might better stratify the risk of recurrence and prognosis in breast cancer patients.
KEY POINTS: • Association of response evaluation after neoadjuvant chemotherapy by pathology and MRI allows better stratification of prognosis. • Complete response to neoadjuvant chemotherapy on pathology and MRI was related to better disease-free survival. • Complete response on MRI or pathology only had a greater risk of recurrence.
引用
- Bitencourt AGV, Pires BS, Calsavara VF, et al. Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study. Eur Radiol. 2021. PMID: 34036420. doi:10.1007/s00330-021-08042-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。